Hims & Hers Health, Inc. Class A Common Stock (HIMS)
25.03
-4.11 (-14.10%)
NYSE · Last Trade: May 12th, 7:13 PM EDT
Detailed Quote
Previous Close
29.14
Open
25.21
Bid
24.70
Ask
24.75
Day's Range
24.56 - 26.84
52 Week Range
13.74 - 70.43
Volume
53,509,246
Market Cap
4.80B
PE Ratio (TTM)
49.08
EPS (TTM)
0.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
35,340,771
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.
Next-generation wellness platforms targeting longevity, metabolism, and performance continue gaining momentum in one of healthcare’s fastest-growing sectors
Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market’s revenue expectations in Q1 CY2026 as sales rose 3.8% year on year to $608.1 mill...
Hims & Hers Health (NYSE:HIMS) reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company’s weight-loss business is creating short-term margin pressure and volatility in GAAP results.
On the company’s earnings call
Telehealth company Hims & Hers Health (NYSE:HIMS) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 3.8% year on year to $608.1 million. O...
Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2026. Moving forward, the Company plans to transition to an annual rather than quarterly shareholder letter and will continue to provide regular updates through a quarterly earnings call, earnings release, and supplemental materials.
Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting results this Monday after the bell. Here’s what to expect. Hims & Hers Health met analyst...
As Hims & Hers pivots to branded GLP-1s via a Novo Nordisk deal, all eyes are on the company’s May 11 earnings as investors look for sustained subscriber growth.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...
What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 4% in the afternoon session after the stock's momentum weakened as Amazon.com...
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, has nominated Kofi Amoo-Gottfried for election as a new director at the company’s 2026 annual shareholder meeting in June.
What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 9.6% in the afternoon session after JPMorgan initiated coverage on the comp...
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...
